Clinical Domain Working Groups

The intent is to define gene specifications of the ACMG/AMP rules for the classification of variants in the non-BRCA1/2, non-MMR DNA repair associated breast, ovarian and pancreatic cancer predisposition genes (ATM, BARD1, BRIP1, CHEK2, RAD51C, RAD51D, and PALB2). These genes are all involved in homologous recombination DNA repair and/or cell cycle regulation in response to DNA damage and are often tested concurrently using multigene clinical hereditary cancer testing panels when evaluating patients for mutations conferring increased risk of breast, ovarian, and pancreatic cancer.